Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0019693 (
HIV
)
170,526
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
In Old World primates,
TRIM5
-alpha confers a potent block to human immunodeficiency virus type 1 (HIV-1) infection that acts after virus entry into cells. Cyclophilin A (CypA) binding to viral capsid protects
HIV
-1 from a similar activity in human cells. Among New World primates, only owl monkeys exhibit post-entry restriction of
HIV
-1 (ref. 1). Paradoxically, the barrier to
HIV
-1 in owl monkey cells is released by capsid mutants or drugs that disrupt capsid interaction with CypA. Here we show that knockdown of owl monkey CypA by RNA interference (RNAi) correlates with suppression of anti-
HIV
-1 activity. However, reintroduction of CypA protein to RNAi-treated cells did not restore antiviral activity. A search for additional RNAi targets unearthed TRIMCyp, an RNAi-responsive messenger RNA encoding a
TRIM5
-CypA fusion protein. TRIMCyp accounts for post-entry restriction of
HIV
-1 in owl monkeys and blocks
HIV
-1 infection when transferred to otherwise infectable human or rat cells. It seems that TRIMCyp arose after the divergence of New and Old World primates when a LINE-1 retrotransposon catalysed the insertion of a CypA complementary DNA into the
TRIM5
locus. This is the first vertebrate example of a chimaeric gene generated by this mechanism of exon shuffling.
...
PMID:Cyclophilin A retrotransposition into TRIM5 explains owl monkey resistance to HIV-1. 1524 29
TRIM5
is a determinant of species-specific differences in susceptibility to infection by retroviruses bearing particular capsids. Human immunodeficiency virus type 1 (HIV-1) infection is blocked by the alpha isoform of macaque
TRIM5
(TRIM5alpha(rh)) or by the product of the owl monkey
TRIM5
-cyclophilin A gene fusion (TRIMCyp). Human TRIM5alpha potently restricts specific strains of murine leukemia virus (N-MLV) but has only a modest effect on
HIV
-1. The amino termini of
TRIM5
orthologues are highly conserved and possess a coiled-coil domain that promotes homomultimerization. Here we show that heterologous expression of TRIM5alpha(rh) or TRIMCyp in human cells interferes with the anti-N-MLV activity of endogenous human TRIM5alpha (TRIM5alpha(hu)). Deletion of the cyclophilin domain from TRIMCyp has no effect on heteromultimerization or colocalization with TRIM5alpha(hu) but prevents interference with anti-N-MLV activity. These data demonstrate that
TRIM5
orthologues form heteromultimers and indicate that C-terminal extensions alter virus recognition by multimers of these proteins.
...
PMID:Disruption of human TRIM5alpha antiviral activity by nonhuman primate orthologues. 1591 43
The peptidyl-prolyl isomerase cyclophilin A (CypA) embraces an exposed, proline-rich loop on
HIV
-1 capsid (CA) and renders reverse transcription complexes resistant to an antiviral activity in human cells. A CypA fusion with
TRIM5
that is unique to New World owl monkeys also targets
HIV
-1 CA, but this interaction potently inhibits infection. A similar block to
HIV
-1 infection in Old World monkeys is attributable to the alpha isoform of the
TRIM5
orthologue in these species. To determine whether
HIV
-1 restriction by Old World monkey TRIM5alpha is modulated by the CA-CypA interaction, RNA interference was used to disrupt CypA in cells from African green monkeys and rhesus macaques.
HIV
-1 infectivity increased in response to CypA knock-down to the same extent that it increased in response to
TRIM5
knock-down. CypA knock-down eliminated the
HIV
-1 stimulatory effect of cyclosporin A (CsA), a competitive inhibitor of the CypA-CA interaction, or of CA mutants that block binding to CypA but caused no change in titer of retroviruses that don't interact with CypA. Simultaneous knock-down of both CypA and
TRIM5
caused minimal additional increase in titer, suggesting that CypA inhibits
HIV
-1 replication in these cells because it is required for CA recognition by TRIM5alpha. Finally, CsA increased
HIV
-1 titer in otherwise nonrestrictive feline cells but only after these cells were transduced with Old World monkey TRIM5alpha. Thus, CypA is required for
HIV
-1 restriction by Old World monkey orthologues of TRIM5alpha.
...
PMID:Cyclophilin A is required for TRIM5{alpha}-mediated resistance to HIV-1 in Old World monkey cells. 1620 99
The intracellular TRIM5alpha protein successfully inhibits
HIV
-1 infection in rhesus monkeys, but not in humans . A few amino acids in the virus-interacting SPRY domain were found to be responsible for most of this anti-viral specificity , raising the possibility that genetic variation among humans could result in TRIM5alpha proteins with a spectrum of potencies. We found several nonsynonymous SNPs at the human
TRIM5
locus, but only one of these (H43Y) was found to have a significant functional consequence. We demonstrate that H43Y impairs TRIM5alpha restriction of two distantly related retroviruses. H43Y lies in the RING domain of TRIM5alpha and may negatively affect its putative E3 ubiquitin ligase activity. This detrimental allele dates back to before the African diaspora and is found at a frequency of 43% in indigenous Central and South Americans. We suggest that relaxed constraint due to a recent period of low retroviral challenge has allowed the deleterious H43Y mutation to persist and even to expand after the bottleneck that occurred upon human migration to the New World. The unexpectedly high frequency of an impaired retroviral restriction allele among humans is likely to have a significant impact on our ability to ward off future retroviral challenges.
...
PMID:High-frequency persistence of an impaired allele of the retroviral defense gene TRIM5alpha in humans. 1640 28
Arsenic trioxide (As(2)O(3)) increased human immunodeficiency virus type 1 (HIV-1) infectivity when particular Homo sapiens and Cercopithecus aethiops cell lines were used as targets. Knockdown of human TRIM5alpha by RNA interference eliminated the As(2)O(3) effect, demonstrating that the drug acts by modulating the activity of this retroviral restriction factor. In contrast,
HIV
-1 infectivity in target cell lines from other primate species (Cercopithecus tantalus, Macaca mulatta, and Aotus trivirgatus) was not increased by As(2)O(3), despite the potent
TRIM5
-dependent
HIV
-1 restriction activity that these cells exhibit. To determine if As(2)O(3) responsiveness is characteristic of particular
TRIM5
orthologues and not others,
TRIM5
cDNAs from these five primate species were transduced into cat fibroblasts, which lack endogenous
HIV
-1 restriction activity and, therefore, responsiveness to As(2)O(3). In this context, the
HIV
-1 restriction activity conferred by all
TRIM5
orthologues was largely eliminated by As(2)O(3). The effect of As(2)O(3) on
HIV
-1 restriction is thus shared by different
TRIM5
orthologues but dependent on factors specific to the cell line in which
TRIM5
is expressed.
...
PMID:Arsenic counteracts human immunodeficiency virus type 1 restriction by various TRIM5 orthologues in a cell type-dependent manner. 1643 61
The innate antiviral factor TRIM5alpha restricts the replication of some retroviruses through its interaction with the viral capsid protein, leading to abortive infection. While overexpression of human TRIM5alpha results in modest restriction of human immunodeficiency virus type 1 (HIV-1), this inhibition is insufficient to block productive infection of human cells. We hypothesized that polymorphisms within
TRIM5
may result in increased restriction of
HIV
-1 infection. We sequenced the
TRIM5
gene (excluding exon 5) and the 4.8-kb 5' putative regulatory region in genomic DNA from 110
HIV
-1-infected subjects and 96 exposed seronegative persons, along with targeted gene sequencing in a further 30
HIV
-1-infected individuals. Forty-eight single nucleotide polymorphisms (SNPs), including 20 with allele frequencies of >1.0%, were identified. Among these were two synonymous and eight nonsynonymous coding polymorphisms. We observed no association between
TRIM5
polymorphism in
HIV
-1-infected subjects and their set-point viral load after acute infection, although one
TRIM5
haplotype was weakly associated with more rapid CD4(+) T-cell loss. Importantly, a
TRIM5
haplotype containing the nonsynonymous SNP R136Q showed increased frequency among
HIV
-1-infected subjects relative to exposed seronegative persons, with an odds ratio of 5.49 (95% confidence interval = 1.83 to 16.45; P = 0.002). Nonetheless, we observed no effect of individual TRIM5alpha nonsynonymous mutations on the in vitro
HIV
-1 susceptibility of CD4(+) T cells. Therefore, any effect of TRIM5alpha polymorphism on
HIV
-1 infection in primary lymphocytes may depend on combinations of SNPs or on DNA sequences in linkage disequilibrium with the TRIM5alpha coding sequence.
...
PMID:Genetic association of the antiviral restriction factor TRIM5alpha with human immunodeficiency virus type 1 infection. 1647 53
In owl monkeys, a retrotransposition event replaced the gene encoding the retroviral restriction factor TRIM5alpha with one encoding TRIMCyp, a fusion between the RING, B-box 2 and coiled-coil domains of
TRIM5
and cyclophilin A. TRIMCyp restricts human immunodeficiency virus (
HIV
-1) infection by a mechanism dependent on the interaction of the cyclophilin A moiety and the
HIV
-1 capsid protein. Here, we show that infection by retroviruses other than
HIV
-1 can be restricted by TRIMCyp, providing an explanation for the evolutionary retention of the TRIMCyp gene in owl monkey lineages. The TRIMCyp-mediated block to
HIV
-1 infection occurs before the earliest step of reverse transcription. TRIMCyp-mediated restriction involves at least two functions: (1) capsid binding, which occurs most efficiently for trimeric TRIMCyp proteins that retain the coiled-coil and cyclophilin A domains, and (2) an effector function that depends upon the B-box 2 domain.
...
PMID:Requirements for capsid-binding and an effector function in TRIMCyp-mediated restriction of HIV-1. 1665 Apr 49
Tripartite motif 5alpha (TRIM5alpha) restricts some retroviruses, including human immunodeficiency virus type 1 (HIV-1), from infecting the cells of particular species. TRIM5alpha is a member of the TRIM family of proteins, which contain RING, B-box, coiled-coil (CC), and, in some cases, B30.2(SPRY) domains. Here we investigated the abilities of domains from TRIM proteins (TRIM6, TRIM34, and TRIM21) that do not restrict
HIV
-1 infection to substitute for the domains of rhesus monkey TRIM5alpha (TRIM5alpha(rh)). The RING, B-box 2, and CC domains of the paralogous TRIM6 and TRIM34 proteins functionally replaced the corresponding TRIM5alpha(rh) domains, allowing
HIV
-1 restriction. By contrast, similar chimeras containing the components of TRIM21, a slightly more distant relative of
TRIM5
, did not restrict
HIV
-1 infection. The TRIM21 B-box 2 domain and its flanking linker regions contributed to the functional defectiveness of these chimeras. All of the chimeric proteins formed trimers. All of the chimeras that restricted
HIV
-1 infection bound the assembled
HIV
-1 capsid complexes. These results indicate that heterologous RING, B-box 2, and CC domains from related TRIM proteins can functionally substitute for TRIM5alpha(rh) domains.
...
PMID:Functional replacement of the RING, B-box 2, and coiled-coil domains of tripartite motif 5alpha (TRIM5alpha) by heterologous TRIM domains. 1677 7
The peptidyl-prolyl isomerase cyclophilin A (CypA) binds a proline-rich loop on the surface of
HIV
-1 capsid (CA). This interaction increases
HIV
-1 infectivity in humans but promotes an anti-
HIV
-1 restriction activity in non-human primates. Efforts to understand these paradoxical effects of cyclophilin, along with more targeted approaches to uncover the genetic basis for
HIV
-1 restriction, led to the discovery of
TRIM5
(tripartite motif protein 5), a CA-specific receptor for the retroviral core. The ensuing
TRIM5
publication flurry established a paradigm of innate immunity in which the protein lattice of an invading retroviral core, rather than double-stranded RNA or lipopolysaccharide, is recognized by a multimeric, cytoplasmic receptor. CypA modulates
HIV
-1 virion core detection by this class of innate pattern recognition molecule, apparently by inducing subtle shifts in CA conformation.
...
PMID:Cyclophilin, TRIM5, and innate immunity to HIV-1. 1681 34
TRIM5alpha is a potent inhibitor of infection by diverse retroviruses and is encoded by one of a large family of TRIM genes. We found that several TRIM motifs among a panel of selected human TRIM proteins (TRIM1, 5, 6, 18, 19, 21 22, 34) could inhibit infection when artificially targeted to an incoming
HIV
-1 capsid. Conversely, when ectopically expressed as authentic full-length proteins, most lacked activity against a panel of retroviruses. The exceptions were TRIM1,
TRIM5
and TRIM34 proteins. Weak but specific inhibition of
HIV
-2/SIV(MAC) and EIAV by TRIM34 was noted, and human TRIM5alpha modestly, but specifically, inhibited an
HIV
-1 strain carrying a mutation in the cyclophilin binding loop (G89V). Restriction activity observed in ectopic expression assays was sometimes not detectable in corresponding RNAi-based knockdown experiments. However, endogenous owl monkey TRIMCyp potently inhibited an SIV(AGM) strain. Overall, sporadic examples of intrinsic antiretroviral activity exist in this panel of TRIM proteins.
...
PMID:Antiretroviral potential of human tripartite motif-5 and related proteins. 1682 31
1
2
3
4
5
6
7
8
9
10
Next >>